Identification of the Molecular Mechanisms of non-response to Treatments, Relapses and Remission in Autoimmune, Inflammatory, and Allergic Conditions
Project information
3TR
Grant agreement ID: 831434
Status
Ongoing project
-
Start date
1 September 2019
-
End date
31 August 2026
Funded under:
H2020-EU.3.1.7.
-
Overall budget:
€ 80 803 177,75
-
EU contribution
€ 40 273 191,50
Project description
Identifying reasons for patients’ negative response to treatment
The identification of the molecular mechanisms that can positively or negatively influence a patient’s response to medical treatment is a key issue among health practitioners. A study promoted by 3TR, a consortium of university institutions, SMEs and leading pharmaceutical companies, will address this issue. This EU-funded project will apply bioinformatics and control methods to collect and analyse data from blood, tissues and other fluids during the entire treatment process. It will create a centralised data platform for better management and implement an inclusive molecular and clinical picture of patients experiencing similar diseases. The project intends to explain the role that our microbiome, genetics and regulatory genomics play during treatment.
Topic(s)
IMI2-2018-14-01 - Targeted immune intervention for the management of non-response and relapse
Funding Scheme
IMI2-RIA - Research and Innovation action
Coordinator
FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD
Address
Avenida Americo Vespucio 15 Edif S2
41092 Sevilla
Spain
Activity type
Research Organisations
EU Contribution
€ 9 876 529,68
Participants (69)
THE UNIVERSITY OF MANCHESTER
United Kingdom
EU Contribution
€ 682 941,25
CHRISTIAN-ALBRECHTS-UNIVERSITAET ZU KIEL
Germany
EU Contribution
€ 2 700 000
UNIVERSITY OF LEICESTER
United Kingdom
EU Contribution
€ 523 897,95
EURICE EUROPEAN RESEARCH AND PROJECT OFFICE GMBH
Germany
EU Contribution
€ 1 917 499,43
FUNDACIO CENTRE DE REGULACIO GENOMICA
Spain
EU Contribution
€ 1 665 250
EUROPEAN RESPIRATORY SOCIETY
Switzerland
EU Contribution
€ 361 390,08
FONDAZIONE IRCCS CA' GRANDA - OSPEDALE MAGGIORE POLICLINICO
Italy
EU Contribution
€ 815 450
ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM
Netherlands
EU Contribution
€ 717 221,25
ACADEMISCH ZIEKENHUIS GRONINGEN
Netherlands
EU Contribution
€ 120 875
ALACRIS THERANOSTICS GMBH
Germany
EU Contribution
€ 106 250
ATRYS HEALTH, SA
Spain
EU Contribution
€ 237 562,50
AZIENDA OSPEDALE UNIVERSITA PADOVA
Italy
EU Contribution
€ 277 003,50
AZIENDA OSPEDALIERO-UNIVERSITARIA ANNA MEYER
Italy
EU Contribution
€ 146 350
UNIVERSITEIT GENT
Belgium
EU Contribution
€ 141 508
UNIVERSITAIR ZIEKENHUIS GENT
Belgium
REGION HOVEDSTADEN
Denmark
EU Contribution
€ 201 780
CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE NANCY
France
EU Contribution
€ 825 030,63
UNIVERSITY OF GLASGOW
United Kingdom
EU Contribution
€ 201 000
CHARITE - UNIVERSITAETSMEDIZIN BERLIN
Germany
EU Contribution
€ 541 266,25
AGENCIA ESTATAL CONSEJO SUPERIOR DEINVESTIGACIONES CIENTIFICAS
Spain
EU Contribution
€ 287 500
CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER
Spain
EU Contribution
€ 1 573 843,06
CENTRO DE INVESTIGACION BIOMEDICA EN RED
Spain
EU Contribution
€ 201 512,74
Deutsches Rheuma-Forschungszentrum Berlin
Germany
EU Contribution
€ 229 595
EUROPEAN FEDERATION OF ASTHMA &ALLERGY ASSOCIATIONS IDEELL FORENING
Belgium
EU Contribution
€ 70 416,25
EUROPEAN LUNG FOUNDATION
United Kingdom
EU Contribution
€ 110 675
GENOS DOO ZA VJESTACENJE I ANALIZU
Croatia
EU Contribution
€ 106 501,56
IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE
United Kingdom
EU Contribution
€ 241 798,96
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
France
EU Contribution
€ 125 000
INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES
Portugal
EU Contribution
€ 290 996,25
KAROLINSKA INSTITUTET
Sweden
EU Contribution
€ 584 499,25
LUPUS EUROPE
United Kingdom
EU Contribution
€ 78 750
MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV
Germany
EU Contribution
€ 565 627,50
MEDIZINISCHE HOCHSCHULE HANNOVER
Germany
EU Contribution
€ 285 965
OREBRO UNIVERSITY
Sweden
EU Contribution
€ 893 122,25
OWLSTONE MEDICAL LIMITED
United Kingdom
EU Contribution
€ 139 500
PHILIPPS UNIVERSITAET MARBURG
Germany
EU Contribution
€ 201 565
QUEEN MARY UNIVERSITY OF LONDON
United Kingdom
EU Contribution
€ 2 320 291,36
SERVICIO ANDALUZ DE SALUD
Spain
EU Contribution
€ 1 429 125
SERVICIO MADRILENO DE SALUD
Spain
EU Contribution
€ 387 450
SIP SERVICE S.R.L.
Italy
EU Contribution
€ 201 500
SOCIETE DE PNEUMOLOGIE DE LANGUE FRANCAISE
France
EU Contribution
€ 196 425
STICHTING VUMC
Netherlands
EU Contribution
€ 836 688,75
TECHNISCHE UNIVERSITAET DRESDEN
Germany
EU Contribution
€ 192 500
THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE
United Kingdom
EU Contribution
€ 1 170 877,75
THE QUEEN'S UNIVERSITY OF BELFAST
United Kingdom
EU Contribution
€ 161 201,50
UNIVERSITA DEGLI STUDI DI CATANIA
Italy
EU Contribution
€ 145 302,50
UNIVERSITA DEGLI STUDI DEL PIEMONTE ORIENTALE AMEDEO AVOGADRO
Italy
EU Contribution
€ 294 944,75
UNIVERSITA DEGLI STUDI DI CAGLIARI
Italy
EU Contribution
€ 294 924,76
UNIVERSITA DEGLI STUDI DI GENOVA
Italy
EU Contribution
€ 236 249,38
UNIVERSITA DI PISA
Italy
EU Contribution
€ 292 500
UNIVERSITAT BASEL
Switzerland
EU Contribution
€ 489 568,75
CLINIQUES UNIVERSITAIRES SAINT-LUC
Belgium
EU Contribution
€ 354 942,75
UNIVERSITE DE BRETAGNE OCCIDENTALE
France
EU Contribution
€ 328 000
UNIVERSITEIT HASSELT
Belgium
EU Contribution
€ 247 825
UNIVERSITETET I BERGEN
Norway
EU Contribution
€ 209 617,50
UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN
Ireland
EU Contribution
€ 343 955,31
UNIVERSITY COLLEGE LONDON
United Kingdom
EU Contribution
€ 560 011,25
KATHOLIEKE UNIVERSITEIT LEUVEN
Belgium
EU Contribution
€ 890 500
UNIVERSITY OF SOUTHAMPTON
United Kingdom
EU Contribution
€ 201 498,10
UNIVERSYTET MEDYCZNY W LODZI.
Poland
EU Contribution
€ 80 600
VIB
Belgium
EU Contribution
€ 361 018,75
SANOFI-AVENTIS DEUTSCHLAND GMBH
Germany
JANSSEN PHARMACEUTICA NV
Belgium
TAKEDA DEVELOPMENT CENTRE EUROPE LTD
United Kingdom
ASTRAZENECA AB
Sweden
GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD.
United Kingdom
NOVARTIS PHARMA AG
Switzerland
PFIZER LIMITED
United Kingdom
F. HOFFMANN-LA ROCHE AG
Switzerland
Project information
3TR
Grant agreement ID: 831434
Status
Ongoing project
-
Start date
1 September 2019
-
End date
31 August 2026
Funded under:
H2020-EU.3.1.7.
-
Overall budget:
€ 80 803 177,75
-
EU contribution
€ 40 273 191,50
Project information
3TR
Grant agreement ID: 831434
Status
Ongoing project
-
Start date
1 September 2019
-
End date
31 August 2026
Funded under:
H2020-EU.3.1.7.
-
Overall budget:
€ 80 803 177,75
-
EU contribution
€ 40 273 191,50
Project information
3TR
Grant agreement ID: 831434
Status
Ongoing project
-
Start date
1 September 2019
-
End date
31 August 2026
Funded under:
H2020-EU.3.1.7.
-
Overall budget:
€ 80 803 177,75
-
EU contribution
€ 40 273 191,50
Project information
3TR
Grant agreement ID: 831434
Status
Ongoing project
-
Start date
1 September 2019
-
End date
31 August 2026
Funded under:
H2020-EU.3.1.7.
-
Overall budget:
€ 80 803 177,75
-
EU contribution
€ 40 273 191,50
Deliverables
Deliverables not available
Publications
Publications not available
Project information
3TR
Grant agreement ID: 831434
Status
Ongoing project
-
Start date
1 September 2019
-
End date
31 August 2026
Funded under:
H2020-EU.3.1.7.
-
Overall budget:
€ 80 803 177,75
-
EU contribution
€ 40 273 191,50
Project information
3TR
Grant agreement ID: 831434
Status
Ongoing project
-
Start date
1 September 2019
-
End date
31 August 2026
Funded under:
H2020-EU.3.1.7.
-
Overall budget:
€ 80 803 177,75
-
EU contribution
€ 40 273 191,50
News
Project information
3TR
Grant agreement ID: 831434
Status
Ongoing project
-
Start date
1 September 2019
-
End date
31 August 2026
Funded under:
H2020-EU.3.1.7.
-
Overall budget:
€ 80 803 177,75
-
EU contribution
€ 40 273 191,50
